Lantern Pharma Inc (LTRN)
6.98
+0.83
(+13.50%)
USD |
NASDAQ |
May 06, 13:14
Lantern Pharma Cash from Investing (TTM): -0.9302M for Dec. 31, 2023
Cash from Investing (TTM) Chart
Historical Cash from Investing (TTM) Data
| Date | Value |
|---|---|
| December 31, 2023 | -0.9302M |
| September 30, 2023 | -0.5835M |
| June 30, 2023 | -0.8896M |
| March 31, 2023 | -0.9581M |
| December 31, 2022 | 0.1793M |
| September 30, 2022 | -0.6576M |
| Date | Value |
|---|---|
| June 30, 2022 | -1.586M |
| March 31, 2022 | -19.35M |
| December 31, 2021 | -19.53M |
| September 30, 2021 | -19.30M |
| June 30, 2021 | -18.30M |
| March 31, 2021 | -0.0161M |
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (TTM) Range, Past 5 Years
-19.53M
Minimum
Dec 2021
0.1793M
Maximum
Dec 2022
-6.828M
Average
-0.9442M
Median
Cash from Investing (TTM) Benchmarks
| Eyenovia Inc | -3.970M |
| Cassava Sciences Inc | -0.414M |
| Alpine Immune Sciences Inc | -55.56M |
| Clearside Biomedical Inc | -1.777M |
| Poseida Therapeutics Inc | 39.13M |